The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Navari, Rudolph
One or more keywords matched the following items that are connected to Navari, Rudolph
Item TypeName
Concept Dexamethasone
Academic Article Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
Academic Article Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Academic Article Use of placebos in delayed-emesis studies.
Academic Article Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Academic Article Emerging drugs for chemotherapy-induced emesis.
Academic Article Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Academic Article Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Academic Article Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Academic Article Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Academic Article Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting.
Academic Article A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Academic Article The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Academic Article 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Academic Article Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Academic Article Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
Academic Article Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Academic Article Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Academic Article Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Academic Article Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Academic Article Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
Academic Article Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Academic Article 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Search Criteria
  • Dexamethasone